Cencora’s shares plunged 16.4% following the quarter as investors reacted negatively to the cautious outlook and signs of underlying deceleration despite management’s positive framing of growth and margin initiatives.

• Adjusted diluted EPS rose 7.5% to $4.75, reflecting operational gains but insufficient to reassure the market.
• Consolidated revenue increased 4% to $78.4 billion, driven by growth across segments but with indications of slowing momentum.
• Operating income grew in the U.S. and International Healthcare Solutions segments, yet margin pressures and incremental costs from portfolio optimization weighed on profitability.
• Management highlighted specialty pharmaceuticals expansion and digital investments, but these failed to offset concerns about segment performance and guidance.
• The company resumed opportunistic share repurchases, signaling confidence, but the broader market reaction suggests skepticism about sustainability and outlook.